Black Tie
Health and Wellness
1 |
E-mail this link to your Friends |
|
|
Black Tie
International Magazine:
To Age or Not to Age |
|
|
Leonard
P. Guarente, on NAD and Age Reversal |
Leonard P. Guarente, Ph.D.,
is a molecular
biologist; Novartis Professor of Biology at the
Massachusetts Institute of Technology; and director of the
Paul F. Glenn Lab for Science of Aging. He trained as a
postdoctoral fellow at Harvard with Mark Ptashne and has
been on the faculty of MIT since 1981. His lab identified
SIR2 as the key gene regulating life span in yeast and C.
elegans, and is well known for its work within the area of
longevity. He is the author of over 100 scientific articles
and the
book Ageless Quest: One Scientist's
Search for Genes That Prolong Youth. He is on the editorial
board of Cell, EMBO Reports, Developmental Cell, Genes &
Development, Aging, Trends in Genetics, and Experimental
Gerontology, and is a member of the
French Academie des Sciences,
American Academy of Arts and
Sciences,
Academy of the American
Society for Healthy Aging Investigator and
American
Academy of Microbiology. |
|
Dr.
David Sinclair on NAD and Age Reversal |
|
|
Dr.
David Sinclair on NAD and Age Reversal Part 2 |
|
|
David Sinclair, Ph.D.,
Director of the Paul F. Glenn Laboratories for the
Biological Mechanisms of Aging at Harvard Medical School;
Professor of Pathology, and a Senior Scholar of the Ellison
Medical Foundation. He has a Bachelors of Science and a
Ph.D. in Molecular Genetics from the University of New South
Wales, Sydney. He worked as a postdoctoral researcher at M.I.T. with Leonard Guarente, Ph.D., where he discovered a
cause of aging for yeast and genes that control the aging
process. He was recruited to Harvard Medical School in 1999
and was promoted to professor in 2008. In 2004, he
co-founded Sirtris Pharmaceuticals to treat age-associated
diseases such as diabetes, neurodegenerative diseases, and
cancer. In 2006, he co-founded Genocea Biosciences, a
vaccine discovery and development company, to prevent and
treat infectious diseases in developed and developing
countries. Dr. Sinclair has received awards including The
Australian Commonwealth Prize, a Helen Hay Whitney
Postdoctoral Award, a Leukemia Society Fellowship, a Ludwig
Scholarship, a Harvard-Armenise Fellowship, an American
Association for Aging Research Fellowship, and a Fellowship
and Senior Scholarship from the Ellison Medical Foundation.
He won the Genzyme Outstanding Achievement in Biomedical
Science Award (2005) and
a "Bio-Innovator award" (2006). |
|
Black Tie International Magazine
is working with The Director Robert Kane Pappas
to develop an ongoing Broadcast TV Show
covering Ageing and Medical Innovation.
We will also be organizing luncheon and Receptions
to meet the top Scientists in the field.
Please Contact Robert or Gerard directly
if you wish to be notified of times and venues.
Robert Kane Pappas
rkpappas@optonline.net
Gerard Mc Keon
gerard@blacktiemagazine.com
Cell: 917 691 0564
|
|
|
To Age or Not to Age? |
A Film by Robert
Kane Pappas
http://www.toageornottoage.com
|
|
"This [breakthrough]
ranks with the discovery of DNA."
—Dr. Cynthia Kenyon
Imagine a 120-year-old living like today's 60 year-olds.
Possible? Yes, according to the scientists in Robert Kane
Pappas' new film,
To Age or Not to Age.
The
scientists featured in To Age or Not to Age
have found the means to postpone and possibly mitigate
diseases tied to aging, such as cancer, cardiovascular
disease, neurodegenerative diseases, and diabetes.
Genetically programmed genes that control aging, among them
the SIRT2/SIRT1 genes, when altered, can change our health
and lifespan.
"Our
recurring mistake is thinking our current idea is the last
word"—Robert Kane Pappas
The scientists in To
Age or Not to Age
prove
that traditional understandings of aging "just ain't so."
"People
would age more slowly, stay younger longer, and remain free
of disease for a longer time." —Dr. Cynthia Kenyon
Scientists include:
Steven
N. Austad, Ph.D.,
is a professor in the Department of Cellular & Structural
Biology and the Barshop Institute for Longevity & Aging
Studies at the University of Texas Health Science Center San
Antonio.
Rev.
Nicanor Pier Giorgio Austriaco, O.P., Ph.D.,
is an assistant professor of Biology and an instructor of
Theology at Providence College in Providence, RI. He is
also an Investigator of the Rhode Island-INBRE Program
funded by the National Institutes of Health (NIH), a
scientific advisor at the National Catholic Bioethics
Center, and an ethicist of the Dominican Friars Health Care
Ministry of New York in New York City.
Troy
Duster Ph.D.,
is Professor of Sociology at New York University and
Chancellor’s Professor at the University of California,
Berkeley. He serves on committees for the National Academy
of Sciences, the National Science Foundation, and the Legal
and Social Issues Committee
of the Human Genome Project
Aubrey de Grey, Ph.D.,
is a biomedical gerontologist; the chief science officer of
SENS Foundation, a non-profit charity dedicated to combating
the aging process; and editor-in-chief of Rejuvenation
Research.
Leonard
P. Guarente, Ph.D.,
molecular
geneticist; Novartis Professor of Biology at the
Massachusetts Institute of Technology; director
of the
Paul F. Glenn Lab for Science of Aging
Cynthia
Kenyon,
Ph.D.,
American Cancer Society Research Professor,
Biochem. & Biophysics, at the University of California-San
Francisco; director, UCSF Hillblom Center for the Biology of
Aging
Dr.
Thomas Kirkwood,
professor of Medicine and Director
of the Institute for Aging and Health at Newcastle
University.
Gordon
Lithgow, Ph.D.,
is a biomolecular geneticist; and head of the Lithgow
Lab at the Buck Institute for Age Research.
David
Sinclair, Ph.D.,
is director of the Paul F. Glenn Laboratories for the
Biological Mechanisms of Aging at Harvard Medical School;
Professor of Pathology, and a Senior Scholar of the Ellison
Medical Foundation; and co-founder of Sirtris
Pharmaceuticals and Genocea Biosciences.
Christoph Westphal, Ph.D,
co-founder and
CEO of Sirtris Pharmaceuticuals.
While To Age or Not to
Age profiles the science of aging, it also addresses
some of the moral, religious, practical and economic
implications of increased, lifespan. Who will have access
to the medicine? Who will benefit from the breakthroughs?
Will the price of these compounds make this a drug for the
elites.
There already exists a
potentially catastrophic problem with overpopulation. What
happens if we live even longer? What does that mean for
societal structures, family, marriage, social security? If
we can postpone aging, should we? Or are we arrogantly
challenging the laws of nature? Where does evolution fit
in?
"A
lot of people think we're biologically programmed to die,
but the truth is that we're biologically programmed for
survival. There is no mechanism inside us that turns on to
kill us when a certain period of time has elapsed.
—Dr.
Thomas Kirkwood
|
|
|
Aubrey de Grey, Ph.D.,
is a biomedical gerontologist; the chief science
officer of SENS Foundation, a non-profit charity dedicated
to combating the aging process; and editor-in-chief of
Rejuvenation Research. He received his BA and Ph.D. from the
University of Cambridge in 1985 and 2000 respectively. His
original field was computer science, and he did research in
the private sector for six years in the area of software
verification, before switching to biogerontology in the
mid-1990s. His research interests encompass the causes of
all the accumulating and eventually pathogenic molecular and
cellular side-effects of metabolism (“damage”) that
constitute mammalian aging, and the design of interventions
to repair and/or obviate that damage. He has developed a
possibly comprehensive plan for such repair, termed
Strategies for Engineered Negligible Senescence (SENS),
which breaks aging down into seven major classes of damage
and identifies detailed approaches to addressing each one. A
key aspect of SENS is that it can potentially extend healthy
lifespan without limit, even though these repair processes
will probably never be perfect, as the repair only needs to
approach perfection rapidly enough to keep the overall level
of damage below pathogenic levels. Dr. de Grey has termed
this required rate of improvement of repair therapies
“longevity escape velocity”. Dr. de Grey is a Fellow of both
the Gerontological Society of America and the American Aging
Association, and sits on the editorial and scientific
advisory boards of numerous journals and organizations. |
|
|
Cynthia Kenyon, Ph.D.,
is a geneticists, the American Cancer Society
Research Professor, Biochemistry and Biophysics, at the
University of California-San Francisco; and director of the
UCSF Hillblom Center for the Biology of Aging. She graduated
valedictorian in chemistry and biochemistry from the
University of Georgia in 1976, and received her PhD from MIT
in 1981, where, in Graham Walker’s laboratory, she was the
first to look for genes on the basis of their expression
profiles, discovering that DNA damaging agents activate a
battery of DNA repair genes in E. coli. She then did
postdoctoral studies with Nobel laureate Sydney Brenner at
the MRC Laboratory of Molecular Biology in Cambridge, UK,
studying the development of C. elegans. Since 1986 she has
been at the University of California, San Francisco. In
1993, Kenyon and colleagues’ discovery that a single-gene
mutation could double the lifespan of C. elegans sparked an
intensive study of the molecular biology of aging. These
findings have now led to the discovery that an
evolutionarily conserved hormone signaling system controls
aging in other organisms as well, including mammals. Dr.
Kenyon has received many honors and awards for her
findings. She is a member of the US National Academy of
Sciences, the American Academy of Arts and Sciences, and the
Institute of Medicine and she is a past president of the
Genetics Society of America. |
|
|
Christoph Westphal, Ph.D.,
co-founded Sirtris Pharmaceuticals, Inc. in 2004 and has
since served as Chief Executive Officer. In addition to
leading Sirtris as an independent discovery performance unit
within GlaxoSmithKline (GSK), Dr. Westphal serves as the
Senior Vice President of GSK’s Centre of Excellence for
External Drug Discovery (CEEDD). At the CEEDD, Dr. Westphal
and his team are developing a network of external alliances
with world-class biotech companies to bring breakthrough
medicines into the GSK pipeline. Dr. Westphal is based at
Sirtris, which is located in Cambridge, Massachusetts. Dr.
Westphal also serves as the Scientific Advisory Board Chair
for the Healthy Lifespan Institute, and serves on the Board
of Directors for Alnara Pharmaceuticals, Inc., the Board of
Fellows of Harvard Medical School and the Board of Overseers
of the Boston Symphony Orchestra. Dr. Westphal has been the
lead or senior author on several patent applications and
scientific papers in journals, including Cell, Nature and
Nature Genetic |
|
|
Gordon Lithgow, Ph.D.,
is a biomolecular geneticist; and head of the Lithgow Lab at
the Buck Institute for Age Research. Dr. Lithgow coined the
term Geroscience, which is a new scientific discipline
focused at the intersection of normal aging and chronic
disease. The program, covered in Nature, is funded with a
prestigious National Institutes of Health “Roadmap” grant.
Lithgow’s lab focuses on the relationship between stress and
aging by studying genes that effect lifespan and an animal’s
ability to resist stress. One of the most striking
discoveries to come out of the Lithgow lab involves a study
appearing in Science, which revealed that proteins that
prevent cancer in humans also determine lifespan in the
nematode worm C. elegans. In 1996, Lithgow and colleague Dr
Tom Kirkwood wrote a paper for Science, on the "Mechanisms
and Evolution of Aging", that helped make a paradigm shift
away from conventional assumptions about aging. In 2000,
Lithgow and Buck colleague Simon Melov, reported the first
successful use of drugs to extend lifespan in an animal. The
ground-breaking study, published in Science, involved the
use of antioxidants and the nematode worm, C. elegans.
|
|
|
Leonard P. Guarente, Ph.D.,
is a molecular
biologist; Novartis Professor of Biology at the
Massachusetts Institute of Technology; and director of the
Paul F. Glenn Lab for Science of Aging. He trained as a
postdoctoral fellow at Harvard with Mark Ptashne and has
been on the faculty of MIT since 1981. His lab identified
SIR2 as the key gene regulating life span in yeast and C.
elegans, and is well known for its work within the area of
longevity. He is the author of over 100 scientific articles
and the
book Ageless Quest: One Scientist's
Search for Genes That Prolong Youth. He is on the editorial
board of Cell, EMBO Reports, Developmental Cell, Genes &
Development, Aging, Trends in Genetics, and Experimental
Gerontology, and is a member of the
French Academie des Sciences,
American Academy of Arts and
Sciences,
Academy of the American
Society for Healthy Aging Investigator and
American
Academy of Microbiology. |
|
|
Rev. Nicanor Pier Giorgio Austriaco, O.P., Ph.D.,
is an Assistant Professor of Biology and an Instructor of Theology at
Providence College in Providence, RI. He is also an
Investigator of the Rhode Island-INBRE Program funded by the
National Institutes of Health (NIH), a scientific advisor at
the National Catholic Bioethics Center, and an ethicist of
the Dominican Friars Health Care Ministry of New York in New
York City. He earned his Ph.D. in Biology from the
Massachusetts Institute of Technology, where he was a fellow
of the Howard Hughes Medical Institute. At M.I.T., Fr.
Austriaco worked in the laboratory of Professor Leonard
Guarente on the genetics of aging in the yeast,
Saccharomyces cerevisiae. His laboratory at Providence
College is exploring the genetics of programmed cell death
using the yeasts, Saccharomyces cerevisiae and Candida
albicans, as model organisms. Papers describing his research
have been published in Cell, the Journal of Cell Biology,
and the FEMS Yeast Research, among others. His essays in
bioethics have been published in the National Catholic
Bioethics Quarterly, Studia Moralia, Ethics and Medics, and
the Linacre Quarterly.
|
|
|
Steven N. Austad, Ph.D,
is a professor in the Department of Cellular & Structural
Biology and the Barshop Institute for Longevity & Aging
Studies at the University of Texas Health Science Center San
Antonio. His current research involves the search for ways
to medically slow the rate of human aging. Before moving to
Texas in 2004, he held faculty positions at the University
of Idaho and Harvard University. His studies involve
cellular and molecular investigations of bird and mammal
species that are exceptionally long- or short-lived. Dr.
Austad is a multiple award-winning researcher. He is a
fellow of the Gerontological Society of America, a member of
the board of directors of the American Federation for Aging
Research, and serves on the editorial board of most major
scientific journals in the field. Dr. Austad has published
more than 100 scientific papers and two books, with a third
in progress. He was also co-editor (with Edward J. Masoro)
of the last two editions of the Handbook of the Biology of
Aging. His trade book, Why We Age, has been translated into
seven languages. He formerly served on the Scientific
Advisory Board of National Public Radio. |
|
|
Dr. Thomas Kirkwood
is
Professor of Medicine and Director of the Institute for
Aging and Health at Newcastle University. His research is on
the basic science of aging and how genes as well as
non-genetic factors, such as nutrition, influence health in
old age. He led the UK Foresight Task Force on ‘Healthcare
and Older People’ in 1995, and the 2008 Foresight project on
‘Mental Capital Through Life’, was Specialist Adviser to the
2005 House of Lords Science & Technology Select Committee
inquiry into ‘Aging: Scientific Aspects’ and has served on
the Councils of the UK Biotechnology and Biological Sciences
Research Council and Academy of Medical Sciences. His books
include the award-winning ‘Time of Our Lives: The Science of
Human Aging’, ‘Chance, Development and Aging’ (with Caleb
Finch) and ‘The End of Age’ based on his BBC Reith Lectures
in 2001. He was appointed a Commander of the Order
of the British Empire (CBE) in 2009 |
|
|
Troy Duster Ph.D.,
Professor of Sociology at New York University and
Chancellor’s Professor at the University of California,
Berkeley. He publishes widely across the fields of the
sociology of law, science, deviance, inequality, race and
education. He shattered conceived notions of ethnicity in
genetic research by raising the issue of race identification
at the DNA level. His work proves that race continues to
matter, biologically and socially. As a public intellectual,
he serves on committees for the National Academy of
Sciences, the National Science Foundation, and the Legal and
Social Issues Committee of the Human Genome Project. In
1970, his first book, The Legislation of Morality:
Drugs, Crime, and Law became a classic in the drug
field. He is co-author of Whitewashing Race: The
Myth of a Color-Blind Society (2003), which won the
Benjamin Hooks Award and was a finalist for the C. Wright
Mills Award in 2004. Among his other awards are a Guggenheim
Fellowship at the London School of Economics; an honorary
Doctor of Letters from Williams College; and the
Dubois-Johnson-Frazier Award from the American Sociological
Association. Dr. Duster received his Ph.D.
from Northwestern University. |
|
|
Robert Kane Pappas at the |
Navigate Innovation Briefing: The New Doctor's Bag |
Robert Kane Pappas
was born in New York City and
raised in Westchester County. He was educated at Georgetown
University and New York University Graduate Institute of
Film. After graduating he worked in Cable Television. In
the early 80's he created a non fiction series called the
"Computer Moment"; the pilot featured William H. Macy. He
wrote and directed the Narrative features "Now I Know"
(Lifetime Television) and "Some Fish Can Fly" (Artistic
License - 99). Both films were partly set in Ireland. In
2003 he directed the Documentary Feature "Orwell Rolls In
His Grave" -- a film that investigated the corporate
conglomeration of the New Media and it's effects on our
politics. The film was a culmination of a media critique
that had begun when Mr. Pappas was a graduate film student
at NYU during the hostage crisis and had interviewed the
editor of the New York Post. Mr. Pappas has written a
number of screenplays(the most recent is "Nantucket
Sleighride")- and had received a Parents Choice Award for
his children's videos.
In his new feature
documentary "To Age or not To Age..." he explores the
molecular biology behind aging and the degree to which we
can
now intervene in that process.
|
|
http://www.toageornottoage.com |
|
|
|